Safety of uninterrupted direct oral anticoagulants for ambulatory common atrial flutter catheter ablation: A propensity score-matched cohort study.


Journal

Heart rhythm
ISSN: 1556-3871
Titre abrégé: Heart Rhythm
Pays: United States
ID NLM: 101200317

Informations de publication

Date de publication:
04 2020
Historique:
received: 02 10 2019
pubmed: 11 11 2019
medline: 23 6 2021
entrez: 11 11 2019
Statut: ppublish

Résumé

Same-day home discharge after common atrial flutter catheter ablation (CAFCA) is a feasible, safe, and cost-effective practice, but there are currently no data for patients treated with direct oral anticoagulants (DOAs). We evaluated the safety, efficacy, and feasibility of ambulatory CAFCA in patients treated with DOAs compared with those treated with vitamin K antagonists (VKAs). Patients scheduled for isolated and elective ambulatory CAFCA in our tertiary university center between 2009 and 2019 were included. Propensity score for anticoagulant type was calculated from age, sex, body mass index, HAS-BLED and CHA Propensity score matching yielded 820 patients (mean age 67 ± 11 years). Catheter ablation was performed under uninterrupted VKA (n = 410; international normalized ratio 2.5 ± 0.6) or uninterrupted DOA (n = 410). The procedural success rate was 91%, and the effective same-day discharge rate was 93%. The occurrence of the primary end point, defined as any early and clinically significant bleeding (Bleeding Academic Research Consortium classification ≥ 2) at 1 week, was similar between patients treated with DOAs and those treated with VKAs (2.9% vs 3.7%; P = .70). Female sex, high HAS-BLED score, and prolonged procedure duration were independently associated with the primary end point. Uninterrupted DOA regimens are safe for patients undergoing ambulatory CAFCA in a high-volume center with a dedicated ambulatory unit and standardized procedural and postoperative management.

Sections du résumé

BACKGROUND
Same-day home discharge after common atrial flutter catheter ablation (CAFCA) is a feasible, safe, and cost-effective practice, but there are currently no data for patients treated with direct oral anticoagulants (DOAs).
OBJECTIVE
We evaluated the safety, efficacy, and feasibility of ambulatory CAFCA in patients treated with DOAs compared with those treated with vitamin K antagonists (VKAs).
METHODS
Patients scheduled for isolated and elective ambulatory CAFCA in our tertiary university center between 2009 and 2019 were included. Propensity score for anticoagulant type was calculated from age, sex, body mass index, HAS-BLED and CHA
RESULTS
Propensity score matching yielded 820 patients (mean age 67 ± 11 years). Catheter ablation was performed under uninterrupted VKA (n = 410; international normalized ratio 2.5 ± 0.6) or uninterrupted DOA (n = 410). The procedural success rate was 91%, and the effective same-day discharge rate was 93%. The occurrence of the primary end point, defined as any early and clinically significant bleeding (Bleeding Academic Research Consortium classification ≥ 2) at 1 week, was similar between patients treated with DOAs and those treated with VKAs (2.9% vs 3.7%; P = .70). Female sex, high HAS-BLED score, and prolonged procedure duration were independently associated with the primary end point.
CONCLUSION
Uninterrupted DOA regimens are safe for patients undergoing ambulatory CAFCA in a high-volume center with a dedicated ambulatory unit and standardized procedural and postoperative management.

Identifiants

pubmed: 31707161
pii: S1547-5271(19)30998-1
doi: 10.1016/j.hrthm.2019.11.005
pii:
doi:

Substances chimiques

Anticoagulants 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

592-599

Informations de copyright

Copyright © 2019 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Pierre Ollitrault (P)

Department of Cardiology, Caen University Hospital, Caen, France; Normandie Univ, UniCaen, Caen, France. Electronic address: ollitrault-p@chu-caen.fr.

Mathieu Chequel (M)

Department of Cardiology, Caen University Hospital, Caen, France; Normandie Univ, UniCaen, Caen, France.

Laure Champ-Rigot (L)

Department of Cardiology, Caen University Hospital, Caen, France; Normandie Univ, UniCaen, Caen, France.

Patrick Bittar (P)

Department of Cardiology, Caen University Hospital, Caen, France.

Arnaud Pellissier (A)

Department of Cardiology, Caen University Hospital, Caen, France.

Joachim Alexandre (J)

Department of Cardiology, Caen University Hospital, Caen, France; Normandie Univ, UniCaen, Caen, France; Department of Pharmacology, Caen University Hospital, Caen, France.

Damien Legallois (D)

Department of Cardiology, Caen University Hospital, Caen, France; Normandie Univ, UniCaen, Caen, France.

Paul Milliez (P)

Department of Cardiology, Caen University Hospital, Caen, France; Normandie Univ, UniCaen, Caen, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH